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Abstract.
Background: Chronic obstructive pulmonary disease (COPD) is a major disease burden which accounts for 5% of all deaths
globally, with most of those (>90%) occurring in lower to middle income countries (LMIC). It is also emerging as an important
modifiable dementia risk factor.
Objective: To address the knowledge gap surrounding the nature of the associations between COPD, dementia, and mortality,
and the geographical variation of those associations in LMIC.
Methods: Data from the 10/66 study surveying 15,394 participants (mean age 74 years, 62% female) across 8 countries
was used to estimate the prevalence of self-reported COPD and its association with incident dementia and premature death.
Proportional sub-hazards models using a cumulative incidence function were applied to identify the probability of incident
dementia onset given the risk of premature death, with estimates pooled across countries via random effect meta-analysis.
Results: Over the 3-year follow-up, almost 10% of participants developed dementia and 14% were deceased. COPD was not
significantly associated with dementia incidence except in Cuba. However, fully adjusted models indicated that individuals
with COPD were at a 28% increased risk of premature death, a trend present across most countries when analyzed individually.
Conclusion: The link between COPD and dementia is currently somewhat different and weaker in LMIC than in developed
countries. This may be because premature death in the populations studied mask the development of clinical dementia. Given
the global trend toward increased life expectancy, it is critical that the disease burden associated with COPD be addressed
without delay if a further rise in dementia prevalence associated with COPD is to be avoided in LMIC.
Keywords: Chronic obstructive pulmonary disease, lower to middle income countries, mild cognitive impairment, premature
death, prevalence
INTRODUCTION
The prevalence of dementia is projected to increase
substantially worldwide in the coming decades from
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46.8 million in 2015 to 131.5 million in 2050 [1].
While currently it is estimated that 58% of people
with dementia live in low to middle-income coun-
tries (LMIC), this proportion is forecast to increase to
68% by mid-century due to the different demographic
profiles of these regions [1].
In the absence of disease modifying treatment
availability and/or affordability, this increase in
dementia prevalence will lead to dramatic increase
in disease burden in countries that can least afford
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it unless non-pharmacological interventions can be
developed to delay the onset of dementia. It is there-
fore essential to better understand the associations
between risk factors and dementia risk in LMICs.
One emerging risk factor particularly relevant
to LMIC is chronic obstructive pulmonary disease
(COPD). COPD is a major disease burden which
accounts for 5% of all deaths globally, with most of
those (>90%) occurring in LMIC (WHO). Its preva-
lence is about 12% worldwide with higher rates in
the Americas (∼15%) and lower rates in South East
Asia (10%) [2]. COPD is characterized by persistent
lung airflow limitation, typically progressive, which
is associated with chronic inflammation of the air-
ways and lungs [3]. Tobacco smoke is the main cause
of COPD worldwide. Both in human and animal mod-
els, tobacco smoke leads to an inflammatory response
within minutes or hours of inhalation [4, 5]. Sustained
use of tobacco leads to chronic lung inflammation
which contributes to lung tissue damage, impairs its
repair, and leads to emphysema, increased risk of
infection, and increased production of mucus [6].
Excess mucus accumulates in smaller airways and
alveoli, and obstructs large airways thus decreas-
ing airflow and total lung capacity [7] and leads to
increasing breathlessness, coughing, and expectora-
tion [8].
The systemic effects of COPD are not completely
understood, but it is thought to increase chronic
peripheral inflammation which can contribute to vas-
cular pathology, including in the brain, increased
apoptosis, accelerated tissue senescence, and neu-
rodegeneration [9–11]. COPD is also thought to
impair cerebral perfusion and promote hypoxia thus
further contributing to neurodegeneration and cog-
nitive impairment [12]. While smoking is the main
cause of COPD, other risk factors including air pollu-
tion, childhood disadvantage, professional exposure
to chemicals, lifestyle (obesity, exercise, diet), and
genetics are also thought to contribute to the devel-
opment of the disease [13].
In high income countries, COPD is associated with
an almost two-fold increased risk of minor and major
neurocognitive disorders [14, 15] and a two-fold
increased risk of premature death [16]. However, lit-
tle is known about the association between COPD and
dementia, and its complex relationship with poverty
and lower life expectancy, in LMIC. Recent evi-
dence suggests that while smoking is also strongly
associated with COPD in LMIC, the main mortal-
ity risk in these countries may be more strongly
linked to poverty and environmental factors than
to smoking [17]. A possible implication of these
findings is that the association between COPD and
dementia risk may be different in LMIC compared
to high income countries. In addition, the lower life
expectancy prevalent in LMIC is likely to mask the
late-life adverse impact of COPD and particularly
with respect to the development of clinical dementia.
It is therefore critical to consider the contribution of
COPD-related mortality when interpreting dementia
risk in LMIC.
Few normative datasets are available to query com-
plex interactions between COPD, dementia risk, and
mortality in LMIC while contrasting regional differ-
ences. The 10/66 study [18] is the first large-scale
study focused on investigating dementia prevalence
and risk factors in large LMIC populations using a
consistent and comparable methodology. Although
the main focus of the study was around the epidemi-
ology of dementia, the scope of the research is much
broader, including other health domains (chronic dis-
eases, disability, frailty, poly-morbidity) and social
aspects of aging.
Leveraging against this rich resource, the aims
of this study were to investigate 1) the prevalence
of COPD and 2) the prospective risk of demen-
tia and mortality attributable to COPD in older
community-living individuals living in 8 LMIC
(Cuba, Dominican Republic, Peru, Venezuela, Mex-
ico, China, India, Puerto Rico) using data from the
10/66 study.
METHODS
Study population
Population-based surveys were carried across
eleven catchment areas across seven low- and middle-
income countries, selected on the basis of a paucity
of information about dementia in those regions
(Dominican Republic, Peru, Venezuela, Mexico,
China, India, and Puerto Rico). This was part of
the baseline phase of the 10/66 Dementia Research
project, described in depth elsewhere [19]. Briefly,
urban and rural catchment areas were identified such
that the sample included both high urban density
and low-population agrarian lifestyles. Participants
were identified by systematic door-knocking of every
household within these precisely defined and mapped
catchment areas. Those aged 65 years and over were
eligible for participation. Initial baseline data collec-
tion took place between 2003 and 2005. Follow-up
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Table 1
Sample selection and size, by country
Site Baseline Lost Follow-up
Int. MC Dementia N (% of baseline Int. Deceased Dementia Censored
(% of baseline N) (% of follow-up (% of follow-up (% of follow-up
int.) int.) int.) int.)
Cuba 2944 13 313 (10.63%) 2618 327 (12.4%) 2291 433 (18.9%) 182 (7.94%) 1676 (73.15%)
Dominican Rep. 2011 3 235 (11.68%) 1773 335 (18.89%) 1438 323 (22.46%) 165 (11.47%) 950 (66.07%)
Peru 1933 9 162 (8.38%) 1762 444 (25.19%) 1318 101 (7.66%) 77 (5.84%) 1140 (86.50%)
Venezuela 1965 61 109 (5.55%) 1795 467 (26.02%) 1328 139 (10.47%) 151 (11.37%) 1038 (78.16%)
Mexico 2003 0 171 (8.53%) 1832 311 (16.97%) 1521 157 (10.32%) 130 (8.55%) 1234 (81.13%)
China 2162 0 137 (6.34%) 2025 193 (9.53%) 1832 380 (20.74%) 207 (11.29%) 1245 (67.97%)
India 2004 3 181 (9.03%) 1820 – – – – –
Puerto Rico 2009 7 233 (11.59%) 1769 399 (22.56%) 1370 170 (12.40%) 153 (11.17%) 1047 (76.43%)
Total 17031 96 1541 (9.05%) 15394 2476 (16.08%) 11098 1703 (15.34%) 1065 (9.60%) 8330 (75.06%)
Int., number of participants interviewed; MC, missing COPD data; N, total number of participants available at baseline; Lost, number of
participants lost between baseline and follow-up. India is excluded from follow-up due to lack of robust dementia information. Urban and
rural populations are pooled to maximize sample size for subsequent analyses.
took place approximately three years later, between
2007 and 2010. Based on the estimated sample size
required to detect the typical dementia prevalence in
this age group (4.5%), a target of ∼1000 individuals
per catchment was set. Response rates ranged from
74% to 98%. Of an initial 17,031 participants, 1,637
participants were excluded due to missing COPD data
or existent dementia diagnoses at baseline (Table 1),
resulting in a sample size of 15,394. The ethical
aspects of this research were approved by ethics com-
mittees local to data collection, and the Institute of
Psychiatry, King’s College London. Written consent
was obtained from participants or next of kin if the
individual lacked capacity. Oral consent, witnessed in
writing by someone literate, was taken from illiterate
participants.
Interviews and key measures
The baseline assessment took 60–180 minutes, and
included self and informant report questionnaires,
structured clinical interviews, and physical examina-
tion on a range of social, physical, and psychological
health topics. This was conducted in the native lan-
guage of each catchment area. COPD was ascertained
via self-report at baseline as in Sousa et al. [20],
via the question “Do you usually cough up phlegm
from your chest first thing in the morning?”. This
is based on findings that show that 75% of individ-
uals suffering from COPD report chronic coughing
and sputum production [21]. In contrast, only 12% of
adults report chronic cough in the general population
[22], and those who do are at a three-fold increased
risk of developing COPD (i.e., 75% of those with
consistent cough/sputum will develop COPD) over
10 years [23]. Dementia was assessed using cross-
culturally specific criteria developed for the 10/66
program [24]. A diagnosis was established based
on a cognitive tests battery, clinical interviews, and
informant reports (including Community Screen-
ing Instrument for Dementia; the CERAD 10 word
list learning and animal naming tests; the Geriatric
Mental State Examination, and the History and Aeti-
ology Schedule – Dementia Diagnosis and Subtype),
and was validated against local clinicians DSM-IV
diagnoses (see Prince et al. [25] for more infor-
mation). The same method was applied at baseline
and follow-up, and death information obtained from
key informants to determine vital status, date of
death of those deceased and a verbal autopsy on
those deceased. As described in Ferri et al. [26],
this consisted of the World Health Organization’s
“Standard Verbal Autopsy Questionnaire 3: Death
of a Person Aged 15 Years and Above”, a formal
interview with individuals familiar with the deceased
persons, as records are typically unavailable). Indi-
viduals who were thought to have died with dementia
(via verbal autopsy) were coded as incident demen-
tia, rather than death. Covariate information was
obtained at baseline. Sex, age, education, smok-
ing status (non-smoker, ex-smoker, current smoker),
physical activity (very, fairly, not very, or not at
all physically active), diabetes (participant told by
a doctor), stroke (participant told by a doctor), haz-
ardous alcohol consumption (more than 14 units per
week for women and more than 21 for men), and
depression (any major depressive episode accord-
ing to F32 depressive episode, specified as mild,
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moderate or severe according to ICD-10 criteria
[27] based on a computerized algorithm, AGECAT,
applied to the Geriatric Mental State Examination
which was administered to all participants [28])
were obtained by self-report. Hypertension was
obtained by self-report, or meeting International
Society for Hypertension criteria [29] during physical
examination.
Statistical analyses
The analysis method was consistent with other
studies in the 10/66 dataset [19]. Analyses were
carried out on STATA (version 14) and R (ver-
sion 3.2.0) for Windows, following procedures used
previously with 10/66 data [30]. The impact of inclu-
sion/exclusion criterion and attrition was evaluated
with t and chi-square tests. The association between
COPD prevalence and covariates (sex, age, educa-
tion, smoking status, physical activity, hypertension,
diabetes, stroke, hazardous alcohol use, and depres-
sion) were investigated via mutually-adjusted preva-
lence ratios from Poisson regression. The prevalence
of COPD at baseline was adjusted for compositional
effects of age (grouped into 65–69, 70–74, and 75–79,
and 80+ rather than specified as a continuous vari-
able to make it more interpretable particularly given
the substantial variation in life expectancy across
countries), sex, and education. After accounting for
household clusters using the sandwich estimator of
variance (vce (robust) command in STATA), these
adjusted prevalence proportions are reported with
robust 95% confidence intervals.
The association between COPD and dementia inci-
dence and COPD and mortality was modelled using
Fine and Gray proportional subhazards model [31], a
cumulative incidence function that disentangles prob-
ability of dementia onset given the risk of competing
events (e.g., death before dementia onset). Urban and
rural populations were pooled to maximize sample
size. Although sensitivity analyses contrasting urban
and rural populations were originally planned, pilot
analyses showed that estimates could not be reliably
computed due to unstable/non-converging models
possibly linked to differences in attrition rates in rural
and urban settings. Both uncontrolled (no covariates)
and fully controlled (adjusting for sex, age, educa-
tion, smoking status, physical activity, hypertension,
diabetes, and stroke) models were fitted. Participants
were nested by household in all models.
All analyses were carried out for each coun-
try separately, and then pooled in a fixed-effects
meta-analysis [32]. Heterogeneity was examined via
Higgin’s I2. Significance was inferred by robust con-
fidence intervals, with alpha set at 0.05.
RESULTS
Sample selection and baseline characteristics
From 15,394 dementia-free participants with
COPD data available at baseline, 2,476 were lost
to follow-up, including all of the data from India
(there was no follow-up in India), resulting in a final
sample of 11,098 (Table 1). Excluded and included
participants did not significantly differ in terms of
smoking status, hypertension, or diabetes. Excluded
participants were significantly older (t = 31.12, 95%
[6.98, 6.15]; mean age of 80.16 versus 73.59) more
likely to be female (χ2 = 26.36, p < 0.01; 69% ver-
sus 62% female), have a higher level of education
(χ2 = 238, p < 0.01; 93% versus 89% having com-
pleted secondary education), and be less physically
active (χ2 = 1749, p < 0.01; 4% versus 95% being
very physically active). COPD prevalence for the
included 11,098 participants is summarized by site
Fig. 1. COPD Prevalence by site. Figures in white boxed refer to
absolute number of individuals with COPD per site, while bars
refer to percentage of total sample at each site with COPD. Note
y axis is truncated at 7%, the zoomed-in view here is to allow
clearer comparisons between sites. Prevalence is unadjusted. See
Supplementary Table 1 for descriptive statistics for covariates, both
overall and grouped by with and without COPD.
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Table 2
Descriptive statistics for sample at baseline, by country, comparing those with and without COPD
Site COPD Sex Age Education Smoking status Physical Activity Hypertension T2DM Stroke Hazardous Depression
status (female) None Some, did not Completed Completed Tertiary Ex Current Fairly often Very often (yes) (yes) (yes) Alcohol (yes) (yes)
complete primary secondary
Cuba Yes 50∗ (43) 75.06 (7.06) 4 (5.33) 33 (5.05) 36 (3.68) 30 (4.13) 12 (2.41) 32∗ (4.23) 47 (8.36) 52 (4.15) 21 (2.91) 82 (3.79) 13∗ (2.39) 12 (5.26) 8 (7.69) 9 (6.25)
No 1855∗ (66) 75.06 (6.94) 71 (94.67) 621 (94.95) 942 (96.32) 696 (95.87) 485 (97.59) 725∗ (95.77) 515 (91.64) 1201 (95.85) 700 (97.09) 2082 (96.21) 530∗ (97.61) 216 (94.74) 96 (92.31) 135 (93.75)
DR Yes 82 (60) 75.23 (7.50) 33 (8.42) 67 (6.56) 20 (5.41) 9 (6.67) 5 (6.85) 46∗ (6.47) 29 (11.65) 22∗ (3.99) 43 (6.05) 97 (6.32) 20 (7.14) 14 (8.00) 18 (7.69) 37∗ (13.31)
No 1243 (66) 75.64 (7.68) 359 (91.58) 954 (93.44) 350 (94.59) 126 (93.33) 68 (93.15) 665∗ (93.53) 220 (88.35) 530∗ (96.01) 668 (93.95) 1439 (93.68) 260 (92.86) 161 (92.00) 216 (92.31) 241∗ (86.69)
Peru Yes 60 (65) 74.76 (7.35) 6 (4.96) 6 (2.60) 35 (4.83) 31 (6.02) 14 (4.38) 20∗ (7.81) 6 (8.82) 36 (4.69) 28 (4.96) 52 (5.43) 7 (4.05) 10 (7.58) 0 (0) 7 (6.86)
No 1117 (61) 75.25 (7.28) 115 (95.04) 225 (97.40) 690 (95.17) 484 (93.98) 95.63 (95.63) 236∗ (92.19) 62 (91.18) 731 (95.31) 537 (95.04) 906 (94.57) 166 (95.95) 122 (92.42) 8 (100) 95 (93.14)
Venezuela Yes 76 (59) 72.18∗ (6.64) 17 (11.11) 30 (6.82) 60 (6.31) 14 (5.30) 8 (8.99) 50∗ (8.10) 25 (11.85) 48∗ (5.47) 10 (2.93) 94 (6.76) 25 (8.12) 18∗ (13.64) 0 (0) 11 (11.58)
No 1130 (50) 75.41∗ (8.40) 136 (88.89) 410 (93.18) 891 (93.69) 250 (94.70) 81 (91.01) 567∗ (91.90) 186 (88.15) 829∗ (94.53) 331 (97.07) 1296 (93.24) 283 (91.88) 114∗ (86.36) 17 (100) 84 (88.42)
Mexico Yes 87 (62) 74.26 (6.61) 42 (7.58) 62 (7.18) 21 (5.98) 8 (6.45) 65.56) 38 (8.52) 6 (3.33) 56 (6.52) 24 (5.56) 87 (6.91) 35 (8.05) 10 (7.09) 4∗ (20.00) 8 (8.70)
No 1181 (63) 74.76 (7.19) 512 (92.42) 802 (92.82) 330 (94.02) 116 (93.55) 102 (94.44) 408 (91.48) 174 (96.67) 803 (93.48) 408 (94.44) 1172 (93.09) 400 (91.95) 131 (92.91) 16∗ (80.00) 84 (91.30)
China Yes 21∗ (40) 73.17∗ (6.11) 16 (1.97) 12 (4.49) 13 (2.31) 10 (2.63) 1 (0.70) 11∗ (8.94) 15 (3.01) 5∗ (0.69) 7 (2.08) 36 (2.76) 9 (4.41) 8∗ (6.30) 1 (1.69) 1 (10.00)
No 1196∗ (57) 74.82∗ (6.60) 795 (98.03) 255 (95.51) 549 (97.69) 370 (97.37) 141 (99.30) 112∗ (91.06) 483 (96.99) 722∗ (99.31) 330 (97.92) 1268 (97.24) 195 (95.59) 119∗ (93.70) 58 (98.31) 9 (90.00)
India Yes 35∗ (37) 71.93 (5.94) 54 (4.96) 28 (6.53) 9 (2.74) 3 (2.68) 0 (0) 7∗ (5.47) 46 (6.88) 63∗ (4.9) 7 (1.74) 36∗ (3.19) 7 (3.76) 1 (3.23) 1 (20.00) 16∗ (9.70)
No 1080∗ (57) 72.69 (6.84) 1034 (95.04) 401 (93.47) 319 (97.26) 109 (97.32) 43 (100) 121∗ (94.53) 623 (93.12) 1223∗ (95.10) 395 (98.26) 1094∗ (96.81) 179 (96.24) 30 (96.77) 4 (80.00) 149∗ (90.30)
Puerto Rico Yes 42 (74) 76.36 (7.42) 6 (8.33) 10 (2.57) 10 (2.41) 19 (2.66) 12 (2.93) 15 (3.38) 4 (3.85) 14∗ (1.50) 2 (0.58) 53∗ (3.53) 22 (3.43) 10∗ (5.95) 1 (3.57) 4∗ (8.70)
No 1305 (67) 75.93 (7.08) 66 (91.67) 379 (97.43) 405 (97.50) 694 (97.34) 398 (97.07) 429 (96.62) 100 (96.15) 922∗ (98.50) 340 (99.42) 1448∗ (96.47) 620 (96.57) 158∗ (94.05) 27 (96.43) 42∗ (91.30)
T2DM, type 2 diabetes mellitus. Values are mean for continuous variables, and counts for categorical variables. Values in brackets () are percentages for categorical variables and SD for continuous
variables. ∗indicates a significant difference between individuals with or without COPD revealed by t (for continuous) or χ2 (for categorical) tests (see Supplementary Table 1 for more information).
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Table 3
Meta-analyzed and mutually adjusted prevalence ratios (PR) estimates [95% confidence intervals] from a Poisson regression for the independent effects of covariates on COPD prevalence at
baseline
Site Sex Age Education Smoking status Physical Activity Hypertension T2DM Stroke Depression Hazardous Coefficient
(female) Ex Current Fairly often Very often (yes) (yes) (yes) (yes) Alcohol (yes)
Cuba 1.82 1 0.82 1.48 2.82 0.91 0.64 0.9 0.65 1.17 1.85 1.38 63.54,
(1.22, 2.72)∗ (0.97, 1.03) (0.69, 1) (0.90, 2.46) (1.76, 4.52)∗ (0.61, 1.34) (0.37, 1.09) (0.61, 1.32) (0.37, 1.15) (0.66, 2.07) (0.95, 3.61) (0.70, 2.70) p < 0.01
DR 1.29 0.99 0.93 1.10 1.99 0.48 0.73 0.78 1.08 0.97 1.93 0.96 48.80,
(0.89, 1.87) (0.97, 1.01) (0.77, 1.13) (0.75, 1.63) (1.28, 3.10)∗ (0.30, 0.78)∗ (0.48, 1.10) (0.54, 1.13) (0.67, 1.75) (0.56, 1.70) (1.28, 2.89)∗ (0.57, 1.62) p < 0.01
Peru 0.68 1 1.07 2.18 2.36 1.08 1.24 1.14 0.79 1.46 1.37 – 927.69,
(0.44, 1.05) (0.98, 1.04) (0.88, 1.29) (1.28, 3.69)∗ (1.79, 2.09)∗ (0.65, 1.79) (0.73, 2.09) (0.73, 1.79) (0.38, 1.67) (0.76, 2.82) (0.63,2.94) p < 0.01
Venezuela 1.65 1.05 1.13 1.37 3.26 0.93 0.62 1.17 1.73 1.04 2.10 – 1570.20,
(0.98, 2.78) (1.02, 1.09)∗ (0.78, 2.4) (0.78, 2.41) (1.72, 6.18)∗ (0.52, 1.66) (0.25, 1.53) (0.54, 2.53) (0.95, 3.15) (0.422, 2.54) (0.87,5.10) p = 0.07
Mexico 1 1 0.94 1.20 0.50 0.80 0.71 0.95 1.20 0.87 1.19 2.79 16.21,
(0.68, 1.47) (0.98, 1.03) (0.98, 1.03) (0.79, 1.84) (0.22, 1.13) (0.55, 1.17) (0.44,1.13) (0.68, 1.33) (0.82, 1.74) (0.45, 1.68) (0.61, 2.33) (1.14, 6.81)∗ p = 0.18
China 1.74 1.04 0.95 3.96 1.79 0.20 0.67 1.24 2.11 1.54 2.39 0.36 71.46,
(0.94, 3.22) (1, 1.08) (0.78, 1.14) (1.76, 8.89)∗ (0.92, 3.49) (0.07, 0.52)∗ (0.29, 1.56) (0.67, 2.28) (0.95, 4.73) (0.70, 3.40) (0.38, 14.9) (0.05, 2.82) p < 0.01
India 2.44 1 0.78 0.75 1.23 0.63 0.21 0.63 0.80 0.94 1.60 3.30 93.94,
(1.57, 3.79)∗ (0.97, 1.04) (0.62, 0.97)∗ (0.30, 1.90) (0.79, 1.92) (0.37, 1.07) (0.08, 0.53)∗ (0.40, 0.97)∗ (0.36, 1.80) (0.12, 7.48) (0.89, 2.86) (1, 10.89) p < 0.01
Puerto Rico 0.54 0.96 1.01 1.60 2.00 0.25 0.06 5.05 0.80 1.60 1.64 1.27 50.74,
(0.28, 1.04) (0.93, 1) (0.79, 1.30) (0.87, 2.93) (0.73, 5.51) (0.13, 0.50)∗ (0.01, 0.41)∗ (1.24, 20.53)∗ (0.47, 1.35) (0.80, 3.22) (0.63, 4.23) (0.29, 5.57) p < 0.01
Pooled 1.29 1.03 0.93 1.43 1.84 0.69 0.69 0.92 1.05 1.18 1.65 0.03
(1.01, 1.51)∗ (0.99, 1.01) (0.87, 0.96)∗ (1.18, 1.72)∗ (1.49, 2.27)∗ (0.58, 0.82)∗ (0.56, 0.86)∗ (0.79, 1.01)∗ (0.86, 1.29) (0.91, 1.52) (1.34, 2.15) (0.02,0.04)
Higgins (I2) 76.2∗ 56.9 13.8∗ 45.5∗ 64.4∗ 69.9 59.30∗ 39.5 35 0 0 99.6
T2DM, type 2 diabetes mellitus. ∗indicates significance at < 0.05. Base group for comparison in sex is female, smoking status is ‘never smoked’, physical activity is ‘very often’, and hypertension,
T2DM and stroke are ‘no’. Figures in brackets are 95% confidence intervals. Coefficients for alcohol consumption in Peru and Venezuela were removed due to substantial instability (estimates
and associated confidence intervals <0.00001), stemming from low hazardous alcohol consumption rates (0.43% in Peru, 1.48% in Venezuela, while the average across other countries is 3.48%)
resulting in no cases of both hazardous alcohol consumption and COPD in these samples.
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Table 4
Associations of COPD with incident 10/66 dementia (competing risk proportional hazards regression), fully-controlled model coefficients
Site Unadjusted 95%L 95%U +Demographic 95%L 95%U †Demographic 95%L 95%U ‡Fully 95%L 95%U
SHR adjusted and health adjusted
SHR adjusted SHR SHR
Cuba 1.86 1.07 3.23∗ 2.16 1.25 3.74∗ 2.13 1.23 3.72∗ 1.95 1.07 3.54∗
Dominican Republic 0.80 0.41 1.56 0.83 0.42 1.64 0.81 0.41 1.60 0.86 0.43 1.69
Peru 0.30 0.04 2.22 0.37 0.05 2.78 0.40 0.05 2.99 0.40 0.05 2.94
Venezuela 1.22 0.66 2.25 0.83 0.42 1.65 0.88 0.43 1.79 1.31 0.50 3.40
Mexico 0.75 0.35 1.60 0.70 0.33 1.54 0.67 0.30 1.49 0.58 0.24 1.37
China 1.21 0.52 2.81 1.12 0.48 2.60 1.15 0.50 2.62 1.14 0.50 2.60
Puerto Rico 0.40 0.09 1.64 0.39 0.10 1.60 0.34 0.08 1.37 0.33 0.08 1.31
All Pooled 0.86 0.56 1.15 0.81 0.52 1.1 0.77 0.49 1.06 0.74 0.43 1.04
Higgins (I2) 14 8.6 17.5 7.24
SHR, sub-hazard ratio, +Accounting for the competing risk of dementia-free death, and adjusted for age, sex, education level. †Additionally
adjusting for smoking, physical activity, and hypertension. ‡Additionally adjusting for depression and hazardous alcohol consumption.
∗indicates significance at < 0.05.
Table 5
Associations of COPD with all cause mortality (cox regression), fully-controlled model coefficients
Site Unadjusted 95%L 95%U Demographic 95%L 95%U Demographic 95%L 95%U Fully 95%L 95%U
SHR adjusted and health adjusted
SHR adjusted SHR SHR
Cuba 1.19 0.81 1.75 1.18 0.8 1.74 1.06 0.71 1.58 1.07 0.73 1.58
Dominican Republic 1.77 1.3 2.39∗ 1.83 1.36 2.46∗ 1.7 1.26 2.29∗ 1.61 1.18 2.2∗
Peru 1.37 0.65 2.89 1.51 0.74 3.1 1.31 0.6 2.88 1.34 0.62 2.9
Venezuela 1.86 1.16 2.97∗ 1.42 0.88 2.28 1.31 0.76 2.26 1.04 0.48 2.26
Mexico 1.63 1.06 2.5∗ 1.52 0.99 2.33 1.44 0.93 2.24 1.35 0.86 2.12
China 1.69 1.09 2.63∗ 1.32 0.79 2.19 1.25 0.77 2.02 1.21 0.75 1.95
India 1.28 0.43 3.79 1.56 0.52 4.69 1.47 0.48 4.51 1.38 0.45 4.27
Puerto Rico 1.55 0.87 2.75 1.55 0.86 2.81 1.33 0.73 2.41 1.36 0.75 2.46
All Pooled 1.52 1.27 1.78∗ 1.51 1.28 1.78∗ 1.39 1.17 1.64∗ 1.32 1.14 1.58∗
Higgins (I2) 0 0 0 0
SHR, sub-hazard ratio, ∗indicates significance at < 0.05.
COPD and mortality
I2 was noticeably low (<0.01 for all models), indi-
cating that variation across studies was most likely
due to heterogeneity rather than chance, thus pooled
effects should be interpreted with caution. Pooled
effects indicated that COPD was significantly associ-
ated with premature death in all (unadjusted to fully
adjusted) models, such that individuals with COPD
had a 28% increased likelihood of premature death
in the fully adjusted models. This association was
significant for most countries in unadjusted mod-
els, but only remained significant across models in
the Dominican Republic (61% increased prevalence
ratio).
Sensitivity analysis
Following the observation that COPD prevalence
was lower than contemporary systematic reviews
may suggest (e.g., [2]), analyses were re-run with
a restricted age range (65–69) in order to align the
current sample with the wider literature (Supple-
mentary Table 2). These models were unstable due
to the low prevalence of dementia at that age (134
cases across all sites). When all participants in this
age range across sites were combined into a sin-
gle analysis (n = 3,441), COPD did not significantly
predict dementia incidence even when it was sole
predictor (HR = 1.52, 95%CI [0.74,3.11], p = 0.25).
While the current competing risk proportional haz-
ards regression approach has established advantages
[33, 34], traditional Cox regression was also run
in order to explore COPD cause-specific hazards
(Table 5). Results were essentially the same, with
both approaches revealing a comparable pattern of
significance and magnitude of effects (Supplemen-
tary Table 3).
DISCUSSION
This study’s main findings were that COPD was not
consistently associated with risk of dementia across
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all LMIC investigated. However, COPD was associ-
ated with premature death when all countries were
pooled together. In addition, a robust association was
detected between COPD and dementia incidence in
Cuba and with premature death in the Dominican
Republic.
A paucity of data on the prevalence of COPD and
its association with incident dementia and prema-
ture death are available for LMIC. This is largely
due to the high costs of conducting such investi-
gations, which puts them out of reach of LMIC’s
fragile economies, and to the methodological diffi-
culties involved in collecting accurate data in these
countries. The method used in the 10/66 study was
specifically developed to overcome these barriers and
further our understanding of dementia prevalence and
risk factors in these communities.
The present research showed that the prevalence
of COPD in the regions studied ranged from 2.41%
in China to 6.82% in the Dominican Republic. Our
findings are therefore substantially lower than world-
wide estimates reported in recent systematic reviews
(∼10–12%) [2]. We can only speculate as to why this
may be the case. A possible explanation is that mor-
tality associated with COPD and its risk factors is
higher in the regions studied and that the relatively
old age of our sample (mean ∼75 years) reflects
in part a survival effect that may have obscured its
association with incident dementia. It is also likely
that the measure of COPD used in this study, a
single, indirect self-report question rather than the
gold standard of spirometry, may not have identi-
fied all cases. Available evidence suggests that the
overwhelming majority of adults with COPD report
chronic cough and sputum production, whereas 10%
or less of those without COPD report these symptoms
[22, 23]. Nevertheless, this measurement limitation
most likely decreased the sensitivity of our anal-
yses. It is also possible this misclassification bias
may be non-differential (e.g., due to higher rates of
pneumonia in dementia) and may have obscured true
associations. Another possible source of misclassifi-
cation was that, while analyses included a wide range
of covariates associated with both COPD and demen-
tia, information on region-specific factors, such as
poorly ventilated indoor heat and cooking sources,
and air pollution levels was unavailable.
It is notable but not unexpected that smoking and
physical activity were associated with COPD preva-
lence at baseline, although these associations did not
reach significance for all countries. Current smok-
ing was positively associated with COPD in most
countries except Mexico, and was associated with a
39% increased risk of having COPD. Past smoking
was also positively associated with COPD in most
countries except India, but was associated with a
slightly lower risk (34%). Relative to findings from a
recent systematic review reporting a 235% increased
risk in ex-smokers and 351% in current smokers,
the present estimates appear relatively low [35]. As
reported by Burney et al., this may be due to the fact
that the poorest people cannot afford to smoke and
therefore countries with the weakest economies are
more likely to have lower COPD rates [17]. In support
of this explanation, we computed the raw correlation
between the gross domestic product (GDP) of the
countries investigated in the present study at the time
of assessment and their prevalence of COPD (exclud-
ing China which was a major outlier with a high GDP
and very low COPD prevalence) and found a positive
association (r = 0.25), though this was not significant
(Fig. 2).
In contrast, physical activity was negatively asso-
ciated with COPD in all countries with those who
exercise fairly regularly or very regularly having a
64% and 54% lower risk of having COPD. How-
ever, these effects only reached significance in the
Dominican Republic, China, India, and Puerto Rico
and the direction of these effects are uncertain as
while exercise may be protective, it is also the case
that COPD limits physical activity. Other measures
associated with COPD at baseline in pooled analyses
included education (9% decreased risk), stroke (22%
increased risk), and depression (81% increased risk),
although the direction and strength of these effects
were not completely consistent across countries (e.g.,
it is possible that COPD limited people’s capacity
to undertake physical activity, rather than lack of
physical activity increasing COPD risk). Contrary
to our expectation, COPD was not associated with
increased dementia risk in most countries except for
Cuba (95% increased likelihood). This is surprising
because in developed countries COPD, and partic-
ularly the reporting of chronic cough and sputum
production, are associated with poorer health out-
comes and increased dementia incidence [14, 15, 21].
A plausible explanation for these findings is that those
affected by COPD in LMIC are less likely to live into
old age when dementia is more likely to manifest.
Indeed life expectancy at birth for the cohort con-
sidered here is approximately 69 years [36] and thus
it is more likely that a greater proportion of those
suffering from chronic diseases such as COPD may
have died before the start of the study. In contrast life
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Fig. 2. GDP and percent of sample with COPD. GDP figures sourced from Classora knowledge base, accessed 30/05/2018. Unadjusted line
of best fit indicates a positive, but non-significant association between GDP and COPD (r = 0.25, p = 0.59), where China is excluded due to
being an extreme outlier.
expectancy in Cuba, where the only significant asso-
ciation was found between COPD and dementia, was
81 years at the start of the study. Alternatively, this
finding may simply reflect methodological issues that
would be expected in a multi-center study (e.g., sam-
pling variation), or be due to the limitations relating
to the COPD measure and the dementia assessment
procedure used.
Similarly, COPD was positively associated with
premature death in all countries but this effect only
reached significance in the Dominican Republic
(61% increased risk). However, unlike for demen-
tia, when estimates were pooled across all countries,
COPD was associated with a 32% increased risk of
premature death. This is consistent with the expla-
nation proposed above suggesting that the lack of
associations found between COPD and dementia may
be due to lower life expectancy. It is also in line with
the literature showing a clear link between COPD
and its underlying pathological processes and mor-
tality [16]. This could be investigated in future work
collecting data on COPD exposure duration. Simi-
larly, a longer time period may provide more sensitive
predictions of future Dementia diagnosis. In the cur-
rent study it is possible individuals not diagnosed
with dementia were actually in the lengthy pre-
morbid phase [37]. Overall, these findings indicate
that the link between COPD and dementia is currently
somewhat different and weaker in LMIC than in
developed countries, and that this difference may be
due to premature death masking the development of
clinical dementia, at least in the older population
studied. The likely role of lower life expectancy in
LMIC in modulating these associations is important
to consider as recent world mortality reports have
indicated that life expectancy is rising quickly in
these countries. An implication for policy is therefore
that unless the disease burden associated with COPD
is addressed without delay, the future prevalence of
dementia will reach substantially higher levels as life
expectancy rises in LMIC.
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